Danish pharmaceutical giant Novo Nordisk's shares rose 3.3% after reports suggested that radical hedge fund Parvus Asset Management is increasing its holdings in an attempt to influence the appointment of its new CEO. The British Financial Times reported the trend on Monday, citing sources familiar with the matter. Diet medicine manufacturer Novo Nordisk ousted CEO Zhou Fude last month, putting pressure on sales as the company's flagship product, Wegovy, faced fierce competition in the US market. Neither Novo Nordisk nor London-based Parvus immediately responded to requests for comment.

Zhitongcaijing · 06/10 08:01
Danish pharmaceutical giant Novo Nordisk's shares rose 3.3% after reports suggested that radical hedge fund Parvus Asset Management is increasing its holdings in an attempt to influence the appointment of its new CEO. The British Financial Times reported the trend on Monday, citing sources familiar with the matter. Diet medicine manufacturer Novo Nordisk ousted CEO Zhou Fude last month, putting pressure on sales as the company's flagship product, Wegovy, faced fierce competition in the US market. Neither Novo Nordisk nor London-based Parvus immediately responded to requests for comment.